Differences in mRNA Expression of Selected Cytochrome P450, Transporters and Nuclear Receptors Among Various Rat Models of Metabolic Syndrome
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70075 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Jan Soukop and 9 co-authors. Institution: Department of Pharmacology at the Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. Major MEDLINE topics: Metabolic Syndrome, RNA, Messenger, Receptors, Cytoplasmic and Nuclear, Cytochrome P-450 Enzyme System. Cited 1 times so far (Crossref); 85 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Palacky University Olomouc, Ministry of Health of the Czech Republic, Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (original language)
Metabolic syndrome (MetS) is a cluster of risk factors that increase the likelihood of developing cardiovascular, metabolic and other diseases. The pharmacological management of MetS often involves polypharmacy, making it essential to understand how drug‐metabolising enzymes, transporters, transcription factors and other proteins involved are affected under different metabolic conditions. This study investigated the relative mRNA expression of key hepatic and intestinal genes involved in drug metabolism, including Cyp1a2 , Cyp3a23 , Cyp2d1 , Cyp2c11 , Cyp2c6 , Cyp2e1 , Cyp7a1 , Cyp2b1 , Cyp2a1 , Abcg5 , Abcg8 , Abcb1 , Nr1i3 , Nr1i2 , Ahr , Gsta1 and Comt , in four nonobese rat models of MetS: hereditary hypertriglyceridaemic (HHTg), spontaneously hypertensive rat (SHR), SHR expressing transgenic human C‐reactive protein (SHR‐CRP), and bilaterally ovariectomised Wistar (W‐OVX), compared to Wistar controls. Gene expression was quantified by RT–PCR with data normalised using the ΔΔ Ct method. Between the models studied, measurements showed significant differences in the liver. The upregulation of Cyp2c6 and Cyp3a23 was observed only in SHR; upregulated Cyp2d1 was found in SHR as well as in HHTg rats. The downregulated Cyp1a2 was measured in a condition of hypertriglyceridemia, postmenopause or hypertension. These findings highlight model‐specific alterations in gene expression that may affect drug metabolism and interactions. The HHTg may be, in particular, a suitable model for preclinical studies focusing on intestinal drug–drug interactions in MetS‐related conditions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology at the Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Department of Microbiology at the Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
ORCID profiles: Jan Soukop
Funding
- Palacky University Olomouc
- Ministry of Health of the Czech Republic
- Ministerstvo Zdravotnictví Ceské Republiky
Cite
APA
Soukop, J., Rácová, Z., Kazdová, L., Zapletalová, I., Poruba, M., Malínská, H., Hüttl, M., Marková, I., Nováková, K., & Večeřa, R. (2025). Differences in mRNA Expression of Selected Cytochrome P450, Transporters and Nuclear Receptors Among Various Rat Models of Metabolic Syndrome. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70075
Vancouver
Soukop J, Rácová Z, Kazdová L, Zapletalová I, Poruba M, Malínská H, et al. Differences in mRNA Expression of Selected Cytochrome P450, Transporters and Nuclear Receptors Among Various Rat Models of Metabolic Syndrome. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70075
BibTeX
@article{Soukop2025,
author = {Soukop, Jan and Rácová, Zuzana and Kazdová, Ludmila and Zapletalová, Iveta and Poruba, Martin and Malínská, Hana and Hüttl, Martina and Marková, Irena and Nováková, Kristýna and Večeřa, Rostislav},
title = {Differences in mRNA Expression of Selected Cytochrome P450, Transporters and Nuclear Receptors Among Various Rat Models of Metabolic Syndrome},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70075}
}
EUVIMED